abs273.txt	background		regorafenib	a	multikinase	inhibitor	that	inhibits	angiogenesis	growth	and	proliferation	prolongs	survival	as	monotherapy	in	patients	withrefractory	colorectal	cancer	this	international	double-blind	placebo-controlled	multicenter	trial	assessed	the	efficacy	of	withfolinic	acid	fluorouracil	irinotecan	(folfiri)	second-line	treatmentfor	metastatic	methods	with	who	progressed	on	first-lineoxaliplatin	fluoropyrimidine	enrolled	at	45	sites	united	states	andireland	stratified	by	prior	bevacizumab	use	were	randomized	2	1	toregorafenib	or	placebo	treatment	consisted	folfiri	days	anddays	15	16	160	mg	4	to	10	18to	24	every	28-day	cycle	crossover	was	not	allowed	primary	endpoint	wasprogression-free	(pfs)	under	assumption	75%	event	rate	180patients	required	for	135	events	achieve	90%	power	detect	hazardratio	(hr)	0	65	1-sided	α	value	results	one	hundred	eighty-one	(120	toregorafenib-folfiri	61	placebo-folfiri)	median	age	62	years	among	these	117	(65%)	received	aflibercept	pfs	longerwith	regorafenib-folfiri	than	placebo-folfiri	(median	6	vs	5	3	months	hr	73	95%	confidence	interval	[ci]	53-1	01	log-rank	p	=	056)	medianoverall	longer	(hr	ci	71-1	44)	response	ratewas	higher	(34%	25%-44%)	placebo-folfiri(21%	11%-33%	07)	grade	3/4	adverse	>5%	absoluteincrease	from	included	diarrhea	neutropenia	febrile	hypophosphatemia	hypertension	conclusions	addition	therapy	formetastatic	only	modestly	prolonged	over	alone	2018	©	american	society
